Video

Dr. Trent on the Impact of COVID-19 on the Treatment of Rare Cancers

Author(s):

Jonathan C. Trent, MD, PhD

Jonathan C. Trent, MD, PhD, sheds light on the impact of COVID-19 on the treatment of rare cancers.

Jonathan C. Trent, MD, PhD, professor and associate director for Clinical Research at the Sylvester Comprehensive Cancer Center, University of Miami Health System, sheds light on the impact of COVID-19 on the treatment of rare cancers.

Please visit www.OncLive.com to watch the entitreity of the MJH Life Sciences News Network, which provides the latest news across a variety of healthcare specialties, and a number of interviews with experts in the medical field, many of which are focused on the ongoing COVID-19 pandemic.

Related Videos
Viktor Grünwald, MD, PhD
Aaron Gerds, MD
Christine M. Lovly, MD, PhD, Ingram Associate Professor of Cancer Research, associate professor, medicine (hematology/oncology), Vanderbilt-Ingram Cancer Center
Haeseong Park, MD, MPH
David L. Porter, MD
Timothy Yap, MBBS, PhD, FRCP
Leo I. Gordon, MD, Abby and John Friend Professor of Oncology Research, professor, medicine (hematology and oncology), Feinberg School of Medicine, Robert H. Lurie Cancer Center
Hetty E. Carraway, MD, MBA, staff associate professor, Department of Medicine, School of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University; member, Immune Oncology Program, Case Comprehensive Cancer Center; vice chair, Strategy and Enterprise Development, Taussig Cancer Institute, Division of Hematologic Oncology and Blood Disorders, Cleveland Clinic
David A. Braun, MD, PhD, assistant professor, medicine (medical oncology), Louis Goodman and Alfred Gilman Yale Scholar, member, Center of Molecular and Cellular Oncology, Yale Cancer Center
Julia Foldi, MD, PhD
Related Content
OncLive On Air
May 30th 2024

Revisit Every OncLive On Air Episode From May 2024

Gina Z. D’Amato, MD
February 9th 2023

D'Amato Discusses Research and Resistance Mechanisms in Sarcoma and Gastrointestinal Stromal Tumor

Jean-Yves Blay, MD, PhD, of Comprehensive Cancer Centre of Lyon
May 9th 2024

Additional 3 Years of Adjuvant Imatinib Maintenance Reduces Recurrence Risk in High-Risk GIST

Somaiah Shares Insight on the Changing Landscapes of GIST, TGCT, and RAS/RAF-Mutant Tumors
December 29th 2022

Somaiah Shares Insight on the Changing Landscapes of GIST, TGCT, and RAS/RAF-Mutant Tumors

R. Lor Randall, MD, FACS, of UC Davis Comprehensive Cancer Center
April 30th 2024

Examining Potential Markers of Osteosarcoma Stem Cells Is at the Forefront of Research

Bradley J. Monk, MD, FACS, FACOG, Florida Cancer Specialists & Research Institute
April 22nd 2024

FAK Inhibition Emerges as a Potential Complementary Treatment Pathway